THYROID IMAGING STUDY
(I-123 as Sodium Iodide)

Overview

• The Thyroid Imaging Study with radioiodine demonstrates the distribution of functioning thyroid tissue, including ectopic tissue, since thyroid tissue is the only tissue that concentrates large amounts of iodine.

Indications

• Evaluation of hyperthyroidism (1-3).
• Evaluation of enlarged glands or glands with nodules (1-3).
• Evaluation of patients who had irradiation of the head and neck in childhood with or without palpable nodules (4,5).
• Evaluation for ectopic thyroid tissue, e.g. struma ovarii (image over pelvis) and lingual thyroid (image upper neck and jaw).
• Evaluation of congenital hypothyroidism (6).

Examination Time

• Initially: 20 minutes for radiopharmaceutical administration.
• Imaging at 6 hours: 30 minutes.

Patient Preparation (7)

• The patient must be off thyroid hormones:
  1. Thyroxine (T-4) for at least 10 days.
  2. Triiodothyronine (T-3) for at least 3 days.
• The patient must not be taking antithyroid medications:
  1. Propylthiouracil (PTU) and tapazole for at least 3 days.
• The patient must not have had intravenous or intrathecal iodinated contrast material (IVP, CT with contrast, myelogram, angiogram) for at least 3 weeks.
• The technologist records a pertinent, standard history on the Thyroid Information Sheet (see below). The nuclear medicine physician records his/her palpation findings on the same form.
Equipment & Energy Windows

- Gamma camera: Small or large field of view.
- Collimator: Pinhole with 5 mm insert.
- Energy windows: 20% window centered at 159 keV.

Radiopharmaceutical, Dose, & Technique of Administration

- Radiopharmaceutical: I-123 as sodium iodide (8-10).
- Dose: 0.5 mCi (18.5 MBq).
- Technique of administration: Oral.

Patient Position & Imaging Field

- Patient position: Supine with the chin tilted up.
- Imaging field: Neck.

Acquisition Protocol

- Begin imaging 6 hours after ingestion of the radiopharmaceutical.

- Acquire a 5 minute ANT image of the thyroid with the collimator 6 cm from the patient’s neck and with a 4 cm radioactive ruler in the field of view (11):
  1. A 6 cm long block can be made as a convenient measuring device.
  2. A 4 cm ruler can be constructed by marking a 4 cm distance on a 5 cm long strip of aluminum. Drops of pertechnetate are then placed at the 4 cm marks and allowed to dry.
  3. The strip is placed vertically in the midline so that the inferior marker is over the suprasternal notch.
  4. Usually the activity in the drops of pertechnetate is high enough that the markers are visible through the I-123 energy window.

- Acquire a second 5 minute ANT image with the distance between the collimator and patient’s neck adjusted so that the thyroid gland fills three quarters of the field of view. Use the persistence scope to determine this distance.

- Acquire 5 minute RAO and LAO oblique images at 35°; again with the thyroid gland filling approximately three quarters of the field of view (12).
• If there is a palpable nodule, an additional 5 minute ANT image should be acquired:
  1. The nuclear medicine physician places a mark on the patient’s skin directly over the center of the palpable nodule.
  2. The technologist then places a radioactive marker on top of the skin mark.
  3. An image may now be exposed or, if the camera is equipped with an electronic marker, the electronic marker can be aligned with the radioactive marker, the radioactive marker removed, and then an image exposed.
  4. In either case, the camera must be positioned so that its central ray (a line perpendicular to the crystal and passing through the pinhole) passes through the palpable nodule (13).

Protocol Summary Diagram

I-123 sodium iodide

<table>
<thead>
<tr>
<th>Action</th>
<th>Delayed pinhole images</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>6 hr</td>
</tr>
<tr>
<td></td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Data Processing

• None.

Optional Maneuvers

• Evaluation of midline activity: If the images show midline radioactivity which may be due to radioactive saliva, have the patient swallow water and repeat the image.

• Imaging of suppressed thyroid tissue with Tl-201 (14):
  1. Perform at least 1 day after I-123 study.
  2. Inject 2 mCi thallous Tl-201 chloride intravenously.
  3. At 15 minutes acquire a 10 minute ANT image of thyroid using a pinhole collimator.

• Thyroid suppression test (15):
  1. Performed to determine if a functioning nodule is autonomous.
  2. Place the patient on 25 µg of triiodothyronine four times a day for three days and repeat the thyroid imaging study.
Principle Radiation Emission Data - I-123 (16)

- Physical half-life = 13.2 hours.

<table>
<thead>
<tr>
<th>Radiation</th>
<th>Mean % per disintegration</th>
<th>Mean energy (keV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma-2</td>
<td>83.3</td>
<td>159.0</td>
</tr>
<tr>
<td>ce-K, gamma-2</td>
<td>13.6</td>
<td>127.2</td>
</tr>
</tbody>
</table>

Dosimetry - I-123 as Sodium Iodine (17,18)

<table>
<thead>
<tr>
<th>Organ</th>
<th>rads/500 µCi</th>
<th>mGy/18.5 MBq</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid</td>
<td>3.75</td>
<td>37.5</td>
</tr>
<tr>
<td>Stomach wall</td>
<td>0.12</td>
<td>1.2</td>
</tr>
<tr>
<td>Ovaries</td>
<td>0.02</td>
<td>0.2</td>
</tr>
<tr>
<td>Red marrow</td>
<td>0.02</td>
<td>0.2</td>
</tr>
<tr>
<td>Liver</td>
<td>0.01</td>
<td>0.1</td>
</tr>
<tr>
<td>Whole body</td>
<td>0.01</td>
<td>0.1</td>
</tr>
<tr>
<td>Testes</td>
<td>0.01</td>
<td>0.1</td>
</tr>
</tbody>
</table>

References


**Normal Findings**


[Return to Table of Content]
THYROID INFORMATION SHEET

Nuclear Medicine Department

Name__________________________  ID________    Age____    Sex____

Referring physician__________________________  Date______________

TECHNOLOGIST TO COMPLETE

Did the patient notice a problem with his/her thyroid or neck?  Yes___    No___

Has the patient had previous thyroid problems?  Yes___    No___

Has the patient had any thyroid surgery?  Yes___    No___

Did the patient have radiation treatments to the face/neck as a child?  Yes___    No___

Has the patient taken thyroid hormones or antithyroid medicines?  Yes___    No___

Has the patient had any intravenous x-ray contrast in the last month?  Yes___    No___

If the patient is having an uptake study, have he/she eaten since last night?  Yes___    No___

Additional pertinent thyroid history: ________________________________________________
_____________________________________________________________________________

Technologist__________________________

PHYSICIAN TO COMPLETE

Neck Palpation Diagram

Check as Appropriate

Normal____
Size: x1__, x1.5__, x2__, x3__
Contour: smooth___, irregular___, multinodular___
Firmness: normal___, firm___, hard___
Single nodule____
  Moves with swallowing___
  Firm____
Gland tender____

Physician__________________________